While revenue was largely flat, net profit fell 37.6% YoY in Q2FY26. EBITDA decreased by 22.4% from last year at ₹94 crore, while the EBITDA margin shrunk 250 basis points at 9.2% from 11.7% a year earlier. Shares of Akums Drugs and Pharmaceuticals ended 3.12% lower at ₹439 on the NSE today, November 13.
